{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:33:00Z","timestamp":1792517580857,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.bcp.2020.114127","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T11:03:53Z","timestamp":1593255833000},"page":"114127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice"],"prefix":"10.1016","volume":"180","author":[{"given":"Brian R.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Jie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.114127_b0005","unstructured":"Gemzar [package insert]. Eli Lilly and Company, Indianapolis, IN, (2014)."},{"issue":"9","key":"10.1016\/j.bcp.2020.114127_b0010","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1200\/JCO.2012.42.7252","article-title":"Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists","volume":"31","author":"Conti","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.bcp.2020.114127_b0015","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J Med."},{"issue":"21","key":"10.1016\/j.bcp.2020.114127_b0020","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.bcp.2020.114127_b0025","first-page":"6110","article-title":"Action of 2',2'-difluorodeoxycytidine on DNA synthesis","volume":"51","author":"Huang","year":"1991","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2020.114127_b0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00685844","article-title":"Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event","volume":"36","author":"Huang","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2020.114127_b0035","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0026-895X(25)09518-5","article-title":"Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine","volume":"38","author":"Heinemann","year":"1990","journal-title":"Mol. Pharmacol."},{"issue":"4 Suppl 11","key":"10.1016\/j.bcp.2020.114127_b0040","first-page":"3","article-title":"Gemcitabine: metabolism, mechanisms of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Semin. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2020.114127_b0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10928-006-9010-8","article-title":"Model-based drug development: the road to quantitative pharmacology","volume":"33","author":"Zhang","year":"2006","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.bcp.2020.114127_b0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.biocel.2014.12.010","article-title":"Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine","volume":"60","author":"Honeywell","year":"2015","journal-title":"Int. J. Biochem. Cell. Biol."},{"issue":"8","key":"10.1016\/j.bcp.2020.114127_b0055","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1158\/1535-7163.MCT-08-0137","article-title":"New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine","volume":"7","author":"Veltkamp","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.bcp.2020.114127_b0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00280-005-0158-5","article-title":"The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro","volume":"58","author":"Pauwels","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2020.114127_b0065","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1158\/1078-0432.CCR-07-4521","article-title":"Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study","volume":"14","author":"Veltkamp","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2020.114127_b0070","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.bjc.6605727","article-title":"Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma","volume":"103","author":"Cham","year":"2010","journal-title":"Br. J. Cancer."},{"issue":"2","key":"10.1016\/j.bcp.2020.114127_b0075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10456-016-9503-z","article-title":"The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth","volume":"19","author":"Yapp","year":"2016","journal-title":"Angiogenesis."},{"issue":"7","key":"10.1016\/j.bcp.2020.114127_b0080","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1535-7163.MCT-10-0201","article-title":"Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer","volume":"9","author":"Tran Cao","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bcp.2020.114127_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193814","article-title":"Meta-analysis of gemcitabine in brief versus prolonged low-dose infusion for advanced non-small cell lung cancer","volume":"13","author":"Dehua","year":"2018","journal-title":"PLoS One."},{"key":"10.1016\/j.bcp.2020.114127_b0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bcp.2019.06.013","article-title":"Mechanisms of gemcitabine oral absorption as determined by in situ intestinal perfusions in mice","volume":"168","author":"Thompson","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2020.114127_b0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/mp049888e","article-title":"Amino acid ester prodrugs of the anticancer agent gemcitabine: Synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport","volume":"2","author":"Song","year":"2005","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.bcp.2020.114127_b0100","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1021\/mp500330y","article-title":"Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine","volume":"11","author":"Drozdzik","year":"2014","journal-title":"Mol. Pharm."},{"issue":"2\u20133","key":"10.1016\/j.bcp.2020.114127_b0105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.mam.2012.11.003","article-title":"Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications","volume":"34","author":"Smith","year":"2013","journal-title":"Mol. Aspects Med."},{"issue":"8","key":"10.1016\/j.bcp.2020.114127_b0110","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.3390\/molecules22081322","article-title":"Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine","volume":"22","author":"Tsume","year":"2017","journal-title":"Molecules."},{"issue":"3","key":"10.1016\/j.bcp.2020.114127_b0115","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ejpb.2013.12.009","article-title":"The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability","volume":"86","author":"Tsume","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.bcp.2020.114127_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2018.06.010","article-title":"Evaluating the intestinal and oral absorption of the prodrug valacyclovir in wildtype and huPepT1 transgenic mice","volume":"155","author":"Epling","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2020.114127_b0125","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-07-4885","article-title":"Modulation of Gemcitabine (2\u2032,2\u2032-Difluoro-2\u2032-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine","volume":"14","author":"Beumer","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2020.114127_b0130","doi-asserted-by":"crossref","unstructured":"B.C. Kuenen, L. Rosen, E.F. Smit, M.R.N. Parson, M. Levi, R. Ruijter, H. Huisman, M.A. Kedde, P. Noordhuis, W.J.F.v.d. Vijgh, G.J. Peters, G.F. Cropp, P. Scigalla, K. Hoekman, H.M. Pinedo, and G. Giaccone, Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors, J Clin Oncol. 20 (6) (2002) 1657-1667.","DOI":"10.1200\/JCO.2002.20.6.1657"},{"issue":"8","key":"10.1016\/j.bcp.2020.114127_b0135","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1124\/dmd.108.021048","article-title":"Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice","volume":"36","author":"Veltkamp","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.bcp.2020.114127_b0140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-012-2017-5","article-title":"In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001\u2013F4, an oral gemcitabine formulation","volume":"71","author":"Hao","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2020.114127_b0145","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1124\/dmd.108.020735","article-title":"Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice","volume":"36","author":"Reddy","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2020.114127_b0150","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1021\/acs.molpharmaceut.0c00131","article-title":"Chemoproteomic Identification of Serine Hydrolase RBBP9 as a Valacyclovir-Activating Enzyme","volume":"17","author":"Shenoy","year":"2020","journal-title":"Mol Pharm."},{"issue":"2","key":"10.1016\/j.bcp.2020.114127_b0155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1021\/mp0499757","article-title":"A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein","volume":"1","author":"Kim","year":"2004","journal-title":"Mol Pharm."},{"issue":"12","key":"10.1016\/j.bcp.2020.114127_b0160","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.1074\/jbc.274.12.8175","article-title":"Cloning and characterization of human guanine deaminase Purification and partial amino acid sequence of the mouse protein","volume":"274","author":"Yuan","year":"1999","journal-title":"J Biol Chem."},{"issue":"18","key":"10.1016\/j.bcp.2020.114127_b0165","doi-asserted-by":"crossref","first-page":"10299","DOI":"10.1016\/S0021-9258(17)39247-5","article-title":"Identification of functional murine adenosine deaminase cDNA clones by complementation in Escherichia coli","volume":"260","author":"Yeung","year":"1985","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2020.114127_b0170","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0026-895X(25)13624-9","article-title":"A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase","volume":"43","author":"Austin","year":"1993","journal-title":"Mol. Pharmacol."},{"issue":"17","key":"10.1016\/j.bcp.2020.114127_b0175","doi-asserted-by":"crossref","first-page":"12983","DOI":"10.1016\/S0021-9258(18)31483-2","article-title":"Primary structure of human deoxycytidylate deaminase and overexpression of its functional protein in Escherichia coli","volume":"268","author":"Weiner","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2020.114127_b0180","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ymthe.2019.11.026","article-title":"The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?","volume":"28","author":"Frances","year":"2020","journal-title":"Mol. Ther."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2020.114127_b0185","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijpharm.2018.02.033","article-title":"Intestinal absorption and activation of decitabine amino acid ester prodrugs mediated by peptide transporter PEPT1 and enterocyte enzymes","volume":"541","author":"Tao","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.bcp.2020.114127_b0190","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/mp800200a","article-title":"Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine","volume":"6","author":"Sun","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2020.114127_b0195","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bcp.2018.08.018","article-title":"Effect of biphenyl hydrolase-like (BPHL) gene disruption on the intestinal stability, permeability and absorption of valacyclovir in wildtype and Bphl knockout mice","volume":"156","author":"Hu","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2020.114127_b0200","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1002\/jps.23258","article-title":"Species difference of esterase expression and hydrolase activity in plasma","volume":"101","author":"Bahar","year":"2012","journal-title":"J. Pharm. Sci."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220303634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220303634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:15:13Z","timestamp":1757769313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220303634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":40,"alternative-id":["S0006295220303634"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114127","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114127"}}